Crescita Therapeutics (CTX) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue was $5.64M, up $2.1M year-over-year, driven by growth in Commercial Skincare and Manufacturing segments, including new skincare assets and higher manufacturing volumes.

• Gross profit increased to $2.64M, with a gross margin of 46.9%, up 2.5 percentage points year-over-year.

• Net loss widened to $1.16M from $0.93M, mainly due to higher SG&A and operating expenses, including $825K in transaction costs related to a pending acquisition.

• Adjusted EBITDA turned positive at $238K, a $917K improvement year-over-year, reflecting operational improvements and exclusion of non-recurring costs.

• Cash and cash equivalents at quarter-end were $8.71M, up $133K from the previous quarter.

Financial highlights

• Operating expenses rose to $3.85M, up $1.22M year-over-year, primarily due to transaction and share-based compensation costs.

• SG&A expenses increased by $1.19M, mainly from acquisition-related legal and advisory fees and higher share-based compensation.

• Cash provided by operating activities was $142K, compared to cash used of $513K in Q1 2025.

• No amounts drawn on the $3.5M revolving credit facility; working capital stood at $10.17M.

• Revenue: $5.64M (Q1 2026) vs. $3.54M (Q1 2025), up $2.1M.

Outlook and guidance

• Management expects sufficient liquidity to fund operations and execute its Four-Pillar Growth Strategy, focusing on operational priorities and a smooth transition pending the ClinActiv Holdings acquisition.

• The pending acquisition by ClinActiv Holdings is expected to close in Q2 2026, subject to shareholder and court approval.